Updates in the Management of Early-Stage Diffuse Large B-Cell Lymphoma

Presenter: Thomas M. Habermann

Several important updates have emerged in the management of early-stage diffuse large B-cell lymphoma. Three trials resulted in the approval of rituximab + cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) for use in these patients internationally. Furthermore, studies have been initiated to determine whether 4 or 6 cycles of this regimen should be administered without radiation therapy (RT). Six cycles of R-CHOP plus central nervous system (CNS) prophylaxis and prophylactic testicular RT are recommended for patients with extranodal disease occupying the testicles. Although controversial, there is a reasonable consensus in the literature to consider 6 cycles of R-CHOP plus involved-site RT and CNS prophylaxis for patients with extranodal disease of the breast. Patients with primary bone and gastric extranodal disease do not seem to derive a significant survival benefit from RT. Molecular subtype evaluations may change treatment approaches.

Disclosures: Dr. Habermann has disclosed serving as a consultant for Seagen, Tess Therapeutics, Lilly, MorphoSys, Incyte, BioGene, and Loxo Oncology.

Correspondence: Thomas M. Habermann, MD, Mayo Clinic Cancer Center, 200 First Street SW, East 10, Rochester, MN 55905. Email: habermann.thomas@mayo.edu
  • 1.

    Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition. Lyon, France: IARC Publication; 2017.

    • Search Google Scholar
    • Export Citation
  • 2.

    Zhang XY, Collins GP, Cutter DJ, et al. Limited-stage diffuse large B-cell lymphoma: current management and challenges. Br J Haematol 2021;194:508517.

  • 3.

    Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet 2019;394:22712281.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Pfreundschuh M, Murawski N, Christofyllaki K, et al. Excellent outcome of elderly patients with favourable-prognosis DLBCL treated with 4 cycles of CHOP/Chlip-14 plus 8 applications of rituximab and a PET-based intensification strategy the includes involved-site radiotherapy (IS-RT): results of the first 120 patients of the OPTIMAL > 60 trial of the DSHNHL [abstract]. Blood 2017;130(Suppl 1):Abstract 1549.

    • Search Google Scholar
    • Export Citation
  • 5.

    Persky DO, Li H, Stephens DM, et al. Positron emission tomography–directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol 2020;38;30033011.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky imited-stage diffuse large B-cell lymphoma. Blood 2018;131:174181.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Sehn LH, Scott DW, Villa D, et al. Long-term follow-up of a PET-guided approach to treatment of limited-stage diffuse large B-cell lymphoma in British Columbia [abstract]. Blood 2019;134:Abstract 401.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 2004;22:30323038.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Thanarajasingam G, Minasian LM, Baron F, et al. Beyond maximum grade: modernizing the assessment and reporting in haematologic malignancies. Lancet Haematol 2018;5:e563598.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Coffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235242.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:31213127.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006:7:379391.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Torka P, Kothari SK, Sundaram S, et al. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Advances 2020;4:253262.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Vitolo U, Chiappella A, Ferreri AJM, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol 2011;29:27662772.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Cheah CY, Campbell BA, Seymour JF, et al. Primary breast lymphoma. Cancer Treat Rev 2014;40:900908.

  • 16.

    Hui D, Proctor B, Donaldson J, et al. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Lymphoma 2010;51:16581667.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Gutiérrez-Garcia G, Colomo L, Villamor N, et al. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 2010;51: 12251232.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018;24:679690.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 556 556 556
PDF Downloads 348 348 348
EPUB Downloads 0 0 0